What is Logicbio Therapeutics's earnings per share (EPS)?

Logicbio Therapeutics (LOGC) reported diluted earnings per share of -$1.09 for fiscal year 2025. This represents a 62.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Logicbio Therapeutics Financials

LOGC

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$23.0M +69.3% YoY

EPS (Diluted) -$1.09 +62.7% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Logicbio Therapeutics (LOGC) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LOGC FY2025 2026-08-13

Lower operating cash burn in the latest year hid a funding-model shift toward debt and away from cash reserves.

Operating cash flow improved from -$94M to -$16M, but that did not mean the business became self-funding. Cash still fell because a balance-sheet rebuild relied on new borrowing, with long-term debt reaching $203.1M as cash ended at just $10.8M.

The prior year shows a thin gross spread: gross profit was only 16.3% of sales, leaving too little room to absorb overhead. That matters because SG&A plus R&D totaled $68M against just $7M of gross profit, so the operating loss was driven by cost structure above the gross line rather than by a one-off charge.

The company moved from a cash-heavy posture to a leveraged posture, with debt-to-equity rising from near-zero to 1.5x. That change left only $10.8M of cash against $222.6M of liabilities, so day-to-day flexibility now depends more on managing obligations than on a large cash buffer.

Financial Health Signals

Financial health score not available

Logicbio Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-10.31

Logicbio Therapeutics scores -10.31, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($518.8M) relative to total liabilities ($222.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Logicbio Therapeutics passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Logicbio Therapeutics reported a net loss of $23.0M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Logicbio Therapeutics generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Net Income

-$23.0M

YoY+69.3%

Logicbio Therapeutics reported -$23.0M in net income in fiscal year 2025. This represents an increase of 69.3% from the prior year.

EPS (Diluted)

-$1.09

YoY+62.7%

Logicbio Therapeutics earned -$1.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 62.7% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$10.8M

YoY-83.6%

Logicbio Therapeutics held $10.8M in cash against $203.1M in long-term debt as of fiscal year 2025.

Shares Outstanding

27M

YoY+2.2%

Logicbio Therapeutics had 27M shares outstanding in fiscal year 2025. This represents an increase of 2.2% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-17.3%

YoY+32.4pp

Logicbio Therapeutics's ROE was -17.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 32.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

YoY-100.0%

Logicbio Therapeutics reported no research and development spending in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

LOGC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LOGC annual income statement

Metric	TTM	FY25	FY24
Revenue	N/A	$0-100.0%	$43.0M
Cost of Revenue	N/A	$0-100.0%	$36.0M
Gross Profit	N/A	$0-100.0%	$7.0M
R&D Expenses	N/A	$0-100.0%	$26.0M
SG&A Expenses	N/A	$31.0M-26.2%	$42.0M
Operating Income	N/A	-$31.0M+60.8%	-$79.0M
Income Tax	N/A	$0-100.0%	$6.0M
Net Income	N/A	-$23.0M+69.3%	-$75.0M
EPS (Diluted)	—	-$1.09+62.7%	-$2.92

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$33.6M+65.5%	$20.3M	N/A	$0-100.0%	$33.8M+4.6%	$32.3M	N/A	$0
Cost of Revenue	$21.1M+59.8%	$13.2M	N/A	N/A	$20.1M-1.5%	$20.4M	N/A	$0
Gross Profit	$12.5M+76.1%	$7.1M	N/A	N/A	$13.7M+15.1%	$11.9M	N/A	$0
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
SG&A Expenses	$11.7M+631.3%	$1.6M	N/A	$3.0M+25.0%	$2.4M-7.7%	$2.6M	N/A	$3.0M
Operating Income	-$2.0M-142.6%	$4.7M	N/A	-$3.0M-129.7%	$10.1M+21.7%	$8.3M	N/A	-$3.0M
Interest Expense	$4.4M+46.7%	$3.0M	N/A	N/A	$5.4M0.0%	$5.4M	N/A	N/A
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$6.3M-470.6%	$1.7M	N/A	-$1.0M-121.3%	$4.7M+62.1%	$2.9M	N/A	-$1.0M
EPS (Diluted)	-$0.14	$8.91	N/A	-$0.07	$24.62+62.2%	$15.18	N/A	-$0.04

Not reported in any period shown, so not listed: Interest Expense.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

LOGC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LOGC annual balance sheet

Metric	FY25	FY24
Total Assets	$407.8M+161.4%	$156.0M
Current Assets	$34.8M-77.7%	$156.0M
Cash & Equivalents	$10.8M-83.6%	$66.0M
Inventory	$10.9M	N/A
Accounts Receivable	$12.1M	N/A
Goodwill	$28.1M	N/A
Total Liabilities	$222.6M+4352.0%	$5.0M
Current Liabilities	$17.9M+258.0%	$5.0M
Long-Term Debt	$203.1M	N/A
Total Equity	$133.0M-11.9%	$151.0M
Retained Earnings	-$3.4B-0.7%	-$3.3B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$968.2M-0.9%	$977.0M+139.6%	$407.8M+87.1%	$218.0M-1.4%	$221.0M	N/A	$156.0M	N/A
Current Assets	$39.7M-1.5%	$40.3M+15.8%	$34.8M-84.0%	$218.0M-1.4%	$221.0M	N/A	$156.0M	N/A
Cash & Equivalents	$11.0M-8.3%	$12.0M+11.1%	$10.8M-89.4%	$102.0M+277.8%	$27.0M+315.4%	$6.5M-90.2%	$66.0M+100.0%	$33.0M
Inventory	$13.4M+7.2%	$12.5M+14.7%	$10.9M	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$13.6M+0.7%	$13.5M+11.6%	$12.1M	N/A	N/A	N/A	N/A	N/A
Goodwill	$148.0M0.0%	$148.0M+426.7%	$28.1M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$676.4M-0.4%	$679.1M+205.1%	$222.6M+189.1%	$77.0M-2.5%	$79.0M	N/A	$5.0M	N/A
Current Liabilities	$21.2M-12.0%	$24.1M+34.6%	$17.9M	$0-100.0%	$3.0M	N/A	$5.0M	N/A
Long-Term Debt	$209.4M-0.2%	$209.8M+3.3%	$203.1M	N/A	N/A	N/A	N/A	N/A
Total Equity	$291.8M-2.0%	$297.9M+124.0%	$133.0M-5.7%	$141.0M-0.7%	$142.0M-2.1%	$145.0M-4.0%	$151.0M-1.3%	$153.0M
Retained Earnings	-$3.3B-0.2%	-$3.3B+0.4%	-$3.4B-0.3%	-$3.3B-0.1%	-$3.3B	N/A	-$3.3B	N/A

LOGC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LOGC annual cash flow statement

Metric	TTM	FY25	FY24
Operating Cash Flow	-$46.1M	-$16.0M+83.0%	-$94.0M
Investing Cash Flow	-$636.6M	-$52.0M+23.5%	-$68.0M
Financing Cash Flow	$480.9M	$72.0M+7300.0%	-$1.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$19.8M-1200.0%	$1.8M+190.0%	-$2.0M+92.3%	-$26.1M-418.3%	$8.2M+110.3%	$3.9M+295.0%	-$2.0M0.0%	-$2.0M
Capital Expenditures	$1.6M+23.1%	$1.3M	N/A	N/A	$1.6M-38.5%	$2.6M	N/A	N/A
Free Cash Flow	-$21.4M-4380.0%	$500K	N/A	N/A	$6.6M+407.7%	$1.3M	N/A	N/A
Investing Cash Flow	-$587.5M-45092.3%	-$1.3M+94.3%	-$23.0M+7.3%	-$24.8M-1450.0%	-$1.6M+38.5%	-$2.6M-107.4%	$35.0M+151.5%	-$68.0M
Financing Cash Flow	$401.0M	$0	$0-100.0%	$79.9M+1501.8%	-$5.7M-159.1%	-$2.2M	$0	$0
Share Buybacks	$0	$0	N/A	N/A	$0-100.0%	$200K	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

LOGC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

LOGC annual financial ratios

Metric	FY25	FY24
Gross Margin	N/A	16.3%
Operating Margin	N/A	-183.7%
Net Margin	N/A	-174.4%
Return on Equity	-17.3%+32.4pp	-49.7%
Return on Assets	-5.6%+42.4pp	-48.1%
Current Ratio	1.94-29.3x	31.20
Debt-to-Equity	1.53+1.5x	0.03

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	37.2%+2.2pp	35.0%	N/A	N/A	40.5%+3.7pp	36.8%	N/A	N/A
Operating Margin	-5.9%-29.1pp	23.2%	N/A	N/A	29.9%+4.2pp	25.7%	N/A	N/A
Net Margin	-18.8%-27.1pp	8.4%	N/A	N/A	13.9%+4.9pp	9.0%	N/A	N/A
Return on Equity	-2.2%-2.7pp	0.6%	N/A	-0.7%-4.0pp	3.3%+1.3pp	2.0%	N/A	-0.7%
Return on Assets	-0.7%-0.8pp	0.2%	N/A	-0.5%-2.6pp	2.1%	N/A	N/A	N/A
Current Ratio	1.87+0.2x	1.67-0.3x	1.94	N/A	73.67	N/A	31.20	N/A
Debt-to-Equity	0.720.0x	0.70-0.8x	1.53+1.0x	0.550.0x	0.56	N/A	0.03	N/A
FCF Margin	-63.7%-66.1pp	2.5%	N/A	N/A	19.5%+15.5pp	4.0%	N/A	N/A

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Btab Ecommerce BBTT

$83.4M

JIVA Tech PLTXF

$292K

Medical Care Technologies Inc MDCE

$325K

Yuka Group Inc YUKA

$2.1M

Kidpik Corp PIKM

$975

Where Logicbio Therapeutics Ranks

Frequently Asked Questions

What is Logicbio Therapeutics's annual revenue?

Logicbio Therapeutics (LOGC) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Logicbio Therapeutics's revenue growing?

Logicbio Therapeutics (LOGC) revenue declined by 100.0% year-over-year, from $43.0M to $0 in fiscal year 2025.

Is Logicbio Therapeutics profitable?

No, Logicbio Therapeutics (LOGC) reported a net income of -$23.0M in fiscal year 2025.

How much debt does Logicbio Therapeutics have?

As of fiscal year 2025, Logicbio Therapeutics (LOGC) had $10.8M in cash and equivalents against $203.1M in long-term debt.

What is Logicbio Therapeutics's return on equity (ROE)?

Logicbio Therapeutics (LOGC) has a return on equity of -17.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Logicbio Therapeutics's operating cash flow?

Logicbio Therapeutics (LOGC) recorded an outflow of $16.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Logicbio Therapeutics's total assets?

Logicbio Therapeutics (LOGC) had $407.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Logicbio Therapeutics have outstanding?

Logicbio Therapeutics (LOGC) had 27M shares outstanding as of fiscal year 2025.

What is Logicbio Therapeutics's current ratio?

Logicbio Therapeutics (LOGC) had a current ratio of 1.94 as of fiscal year 2025, which is generally considered healthy.

What is Logicbio Therapeutics's debt-to-equity ratio?

Logicbio Therapeutics (LOGC) had a debt-to-equity ratio of 1.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Logicbio Therapeutics's return on assets (ROA)?

Logicbio Therapeutics (LOGC) had a return on assets of -5.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Logicbio Therapeutics's cash runway?

Based on fiscal year 2025 data, Logicbio Therapeutics (LOGC) had $10.8M in cash against an annual operating cash burn of $16.0M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Logicbio Therapeutics's Altman Z-Score?

Logicbio Therapeutics (LOGC) has an Altman Z-Score of -10.31, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Logicbio Therapeutics's Piotroski F-Score?

Logicbio Therapeutics (LOGC) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Logicbio Therapeutics's earnings high quality?

Logicbio Therapeutics (LOGC) reported a net loss of $23.0M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.